Arm Announces Earnings Release Date for Fourth Quarter Fiscal Year Ended 2026 April 8, 2026 Arm Holdings plc (NASDAQ: ARM) will report financial results for the fourth quarter of fiscal year 2026 on Wednesday, May 6, 2026, after market close. The company will host a conference call via audio webcast at 14:00 Pacific Time (17:00 Eastern Time / 22:00 British Summer Time) to review its financial results and business outlook. [...]
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth March 27, 2026 Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD [...]
LivaNova to Announce First-Quarter 2026 Results March 25, 2026 LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners [...]
OCP Announces Date of Fourth Quarter and Full Year 2025 Earnings March 25, 2026 OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2025 results on Wednesday, April 1, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers on the OCP Intralinks portal from 9:00 a.m. [...]
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights March 24, 2026 COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile Across three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved before Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4 Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launch Phase 2b/3 trial in PTSD initiating, following FDA acceptance of IND application Successful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028
Kolibri Global Energy Announces Year End Results With a 15% Increase in Production to Over 4,013 BOEPD March 19, 2026 All amounts are in U.S. Dollars unless otherwise indicated: 2025 HIGHLIGHTS Average production for 2025 was 4,013 BOEPD, an increase of 15% compared to 2024 production of 3,478 BOEPD. The increase is due to production from the wells that were drilled and completed in 2025 Net revenues for 2025 were $56.9 million, a decrease of [...]
TITAN Group: Full Year Results 2025 March 19, 2026 Very strong performance delivers another record year
Kolibri Global Energy Inc. Announces 2025 Proved Developed Reserve Increase of 30% and Year End Earnings Call March 18, 2026 Kolibri Global Energy Inc. (the “Company” or “KGEI”) (TSX: KEI, NASDAQ: KGEI) is providing the results of its December 31, 2025, independent reserves evaluation. All amounts are in US$ unless otherwise stated. Wolf Regener, President and CEO, commented: “We are very pleased that our proved developed producing reserves increased by 30 percent due to our [...]
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 2025 March 12, 2026 All economic indicators are positive. Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024); EBITDA at €467.6 million (€410.6 million in 2024); EBIT at €391.7 million (€330.4 million in 2024) Group net profit at €250.9 million (€211.1 million in 2024) Approval of the proposed dividend distribution of €1.35 per share.
Argan, Inc. to Announce Fourth Quarter and Fiscal Year-End 2026 Results and Host Conference Call on Thursday, March 26, 2026 March 12, 2026 Argan, Inc. (NYSE: AGX) (“Argan” or the “Company”) today announced that the Company will release its fourth quarter and fiscal year-end 2026 financial results after the market closes on Thursday, March 26, 2026. Management will host a webcast with an accompanying slide presentation and conference call on Thursday, March 26, 2026 at 5:00 p.m. ET. [...]